DunedinPACE, a DNA methylation biomarker of the pace of aging.
Level 3 - non-randomized controlled study
Longitudinal birth cohort derivation with validation across secondary cohorts
PubMed 35029144 · doi:10.7554/eLife.73420
What was done
Researchers modeled multi-organ biological aging using longitudinal data from the 1972–1973 Dunedin birth cohort, which tracked within-individual decline across 19 physiological indicators over two decades across four time points. Using elastic-net regression restricted to DNA methylation probes with high test-retest reliability, they trained a single-time-point blood biomarker (DunedinPACE). The algorithm was then tested for reliability and predictive validity across five independent external datasets.
What was found
The abstract does not provide specific numerical values, effect sizes, or confidence intervals. It reports that DunedinPACE demonstrated high test-retest reliability, correlated with childhood adversity in young adults, and predicted incident morbidity, disability, and mortality. Effect sizes were reported as comparable to the GrimAge epigenetic clock, with DunedinPACE providing incremental predictive value when combined with GrimAge.
Why it matters
DunedinPACE provides an epigenetic biomarker designed specifically to measure the current rate of biological aging rather than accumulated chronological or biological age, offering a tool to evaluate anti-aging and geroprotective interventions.
Limits
The abstract provides no sample sizes (n) for the training or validation cohorts and reports no exact numerical statistics, effect estimates, or error margins. The biomarker was derived from a single geographic birth cohort, and the abstract does not describe the demographic or ancestral diversity of the validation cohorts.
Cited by
- supports The DunedinPACE aging measure assesses DNA methylation patterns on DNA rather than telomeres.